Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 15/20 | 0.56 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | ESRRG | P62508 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2262498 | 0.98 | HTR7 (0.54) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL4263907 | 0.98 | HTR7 (0.54) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL20784089 | 0.97 | HTR7 (0.59) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL31461321 | 0.88 | HTR7 (0.64) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL30411125 | 0.88 | HTR7 (0.47) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL1664762 | 0.88 | HTR7 (0.47) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL1122373 | 0.88 | HTR7 (0.57) | HTR7NOS3NOS1NOS2 | |
| SCHEMBL12253689 | 0.86 | HTR7 (0.56) | HTR7NOS3NOS1NOS2 | |
| SCHEMBL27894537 | 0.83 | NTSR1 (0.46) | HTR7NOS3NOS1NOS2PRKCI | |
| SCHEMBL23927826 | 0.81 | HTR7 (0.63) | HTR7NOS3NOS1NOS2ESRRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902356-B2 | Thiazolopyridinone derivates as MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1828207-B1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2009-10-28 | — | — | EP | disclosed |
| EP-1730130-A1 | BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| EP-1708698-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006066174-A1 | THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006040526-A1 | QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
| WO-2005063239-A9 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2006-03-09 | — | — | WO | disclosed |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-20050245500-A1 | Beta-ketoamide compounds with MCH antagonistic activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
| WO-2005085221-A1 | BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005063239-A1 | 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245500-A1 | Beta-ketoamide compounds with MCH antagonistic activity | MCHR2, MCHR1, NPY1R | HTR7 561/4885NOS3 1276/4885NOS1 1308/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR7 17/4885NOS3 1343/4885NOS1 1630/4885 |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | HTR7 4068/4885NOS3 788/4885NOS1 1085/4885 |
| US-20050267093-A1 | Amide compounds with MCH antagonistic activity and medicaments comprising these compounds | MCHR1, MC4R, MCHR2 | HTR7 584/4885NOS3 411/4885NOS1 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.